Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update
F Andre, N Ismaila, KH Allison, WE Barlow… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To update recommendations on appropriate use of breast cancer biomarker
assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast …
assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast …
The incidence of breast cancer recurrence 10-32 years after primary diagnosis
RN Pedersen, BÖ Esen, L Mellemkjær… - JNCI: Journal of the …, 2022 - academic.oup.com
Background Extended, more effective breast cancer treatments have increased the
prevalence of long-term survivors. We investigated the risk of late breast cancer recurrence …
prevalence of long-term survivors. We investigated the risk of late breast cancer recurrence …
Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine …
Purpose: Individualized selection of patients with early-stage hormone receptor–positive
(HR+) breast cancer for extended endocrine therapy (EET) is required to balance modest …
(HR+) breast cancer for extended endocrine therapy (EET) is required to balance modest …
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research
F Conforti, L Pala, T De Pas, E Zattarin, C Catania… - Clinical Cancer …, 2024 - AACR
After decades of research, improving the efficacy of adjuvant endocrine therapy (ET) for
early-stage breast cancer becomes increasingly difficult. Beyond technological …
early-stage breast cancer becomes increasingly difficult. Beyond technological …
Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial
LJ van't Veer, EMK Kranenbarg… - JAMA Network …, 2024 - jamanetwork.com
Importance There is a need for biomarkers that predict late recurrence risk and extended
endocrine therapy (EET) benefit among patients with early-stage breast cancer (EBC) …
endocrine therapy (EET) benefit among patients with early-stage breast cancer (EBC) …
Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase …
VCG Tjan-Heijnen, SWM Lammers, SME Geurts… - …, 2023 - thelancet.com
Background The DATA study evaluated the use of two different durations of anastrozole in
patients with hormone receptor-positive breast cancer who were disease-free after 2–3 …
patients with hormone receptor-positive breast cancer who were disease-free after 2–3 …
Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial
Background Hormone receptor (HR)-positive, HER2/neu-negative breast cancers have a
sustained risk of recurrence up to 20 years from diagnosis. TEAM (Tamoxifen, Exemestane …
sustained risk of recurrence up to 20 years from diagnosis. TEAM (Tamoxifen, Exemestane …
Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans …
DC Sgroi, K Treuner, Y Zhang, T Piper… - Breast Cancer …, 2022 - Springer
Background Multiple clinical trials demonstrate consistent but modest benefit of adjuvant
extended endocrine therapy (EET) in HR+ breast cancer patients. Predictive biomarkers to …
extended endocrine therapy (EET) in HR+ breast cancer patients. Predictive biomarkers to …
Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast …
J Richman, A Ring, M Dowsett, I Sestak - Breast Cancer Research and …, 2021 - Springer
Abstract Purpose Clinical Treatment Score at 5 years (CTS5) is a prognostic tool to estimate
distant recurrence (DR) risk after 5 years of endocrine therapy for postmenopausal women …
distant recurrence (DR) risk after 5 years of endocrine therapy for postmenopausal women …